Question - What are the two prototypes of toxicity associated with the development of cardiomyopathy associated with the use of chemotherapeutic agents?
Answer - The cited reference notes “there are 2 cardiotoxicity prototypes: type I is induced by anthracyclines and causes permanent dose-dependent damage; type II is associated with trastuzumab, a molecular-targeting agent, and results in non-dose-related damage, usually reversible on discontinuation. (Truong J et al. Chemotherapy-induced cardiotoxicity: Detection, prevention and management. (2014 Can J Cardiol 30:869-878)